James E Flynn bought $30.0M of Larimar Therapeutics (LRMR)
Executed Jul 31 2025, disclosed Aug 4 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 4 2025), the stock returned +5.7% (delay-adjusted); from the execution session (Jul 31 2025), +9.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
James E Flynn (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Larimar Therapeutics, Inc. (LRMR). Across 1 priced purchase filing, the average 21-session return was -16.6% from execution and -14.2% from disclosure (delay-adjusted; derived). The largest single filing was $70.9M of NUVL (742,574 sh across 2 lots, as filed), executed Nov 24 2025.
Healthcare · Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→5,000,000 sh across 4 lots
Exec Feb 27
Filed Mar 2 · 7:46 PM ET